Human CXCR2 Stable Cell Line-HCT116

CXCR2, also known as CD182 or IL-8 receptor beta, is a seven-transmembrane G protein-coupled receptor encoded by the gene located on human chromosome 2q35. It binds with high affinity to interleukin-8 (CXCL8) and several other CXC chemokines including CXCL1, CXCL2, CXCL3, CXCL5, and CXCL6. Upon ligand binding, CXCR2 activates downstream signaling cascades such as the MAPK/ERK and PI3K/Akt pathways, playing a central role in neutrophil recruitment, angiogenesis, and inflammatory responses. The Human CXCR2 Stable Cell Line-HCT116 is generated by stably transfecting the full-length human CXCR2 coding sequence into the HCT116 colorectal carcinoma cell line, which endogenously expresses negligible levels of CXCR2. This engineered cell line provides a homogeneous and reproducible system for studying CXCR2-mediated signaling and functional responses in a human epithelial cancer background.

This stable cell line is widely used in drug discovery and preclinical research for evaluating CXCR2 antagonists and inhibitors. Researchers can perform ligand-induced calcium mobilization assays, chemotaxis experiments, and receptor internalization studies to characterize compound potency and selectivity. The cell line is also suitable for investigating the role of CXCR2 in tumor progression, including its contributions to cell proliferation, migration, and epithelial-mesenchymal transition. Additionally, it serves as a valuable tool for studying CXCR2 crosstalk with other signaling pathways and for screening potential therapeutic candidates targeting inflammatory diseases and cancers where the CXCL8-CXCR2 axis is implicated. The stable expression ensures consistent assay performance across multiple passages, making it a reliable platform for both basic research and high-throughput screening applications.